Evaluation of bactericidal activities of LY333328, vancomycin, teicoplanin, ampicillin-sulbactam, trovafloxacin, and RP59500 alone or in combination with rifampin or gentamicin against different strains of vancomycin-intermediate Staphylococcus aureus by time-kill curve methods

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 3, 1999, Pages 717-721

  Hershberger, Ellie ^a,b   Aeschlimann, Jeffrey R ^a,b   Moldovan, Tabitha ^a   Rybak, Michael J ^a,b,c  

^a DETROIT RECEIVING HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE; CLINAFLOXACIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; GENTAMICIN; LEVOFLOXACIN; ORITAVANCIN; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; RIFAMPICIN; SULTAMICILLIN; TEICOPLANIN; TETRACYCLINE; TROVAFLOXACIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; GROWTH INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 0032978436     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.3.717     Document Type: Article

References (9)

1. Boyce, J. M., A. A. Medeiros, and K. Hiramatsu. 1997. Clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) from the United States with subpopulations of cells with reduced susceptibility to vancomycin. abstr. LB-15. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Centers for Disease Control and Prevention. 1997. Reduced susceptibility of Staphylococcus aureus to vancomycin - Japan, 1996. Morbid. Mortal. Weekly Rep. 46:624-635.
3. Hackbarth, C. J., H. F. Chambers, and M. A. Sande. 1986. Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. Antimicrob. Agents Chemother. 29:611-613.
4. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-136.
5. Mulazimoglu, L., S. D. Drenning, and R. R. Muder. 1996. Vancomycingentamicin synergism revisited: effect of gentamicin susceptibility of methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 40: 1534-1535.
6. National Committee for Clinical Laboraton Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
7. Palmer, S. M., and M. J. Rybak. 1996. Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrob. Agents Chemother. 40:701-705.
8. Tenover, F. C. (Centers for Disease Control and Prevention). 1998. Personal communication.
9. Vincent, J., J. Venitz, R. Teng, B. A. Baris, S. A. Willavize, R. J. Polzer, and H. L. Freidman. 1997. Pharmacokinetics and safety of trovafloxacin in healthy male volunteers following administration of single intravenous doses of the prodrug, alatrofloxacin. J. Antimicrob. Chemother. 39:75-80.